Melero, Ignacio

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 4,280

Advances in immunotherapy for hepatocellular carcinoma

Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,306

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,273

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,106

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 787

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

Wischhusen, J., Melero, I., & Fridman, W. H. (2020) · Frontiers in Immunology

GDF15 and Related BiomarkersTGF-β signaling in diseases

Cited by 506

Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies

Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 499

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 480

Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., et al. (2017) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotoxicology and immune responses

Cited by 424

Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)

Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research

Immune cells in cancerNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 417

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

Sangro, B., Melero, I., Wadhawan, S., Finn, R. S., Abou-Alfa, G. K., Cheng, A.-L., Yau, T., Furuse, J., Park, J.-W., Boyd, Z., et al. (2020) · Journal of Hepatology

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 407

Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology

Cancer Immunotherapy and BiomarkersCell death mechanisms and regulation

Cited by 385

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors

Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J. C., et al. (2004) · Journal of Clinical Oncology

Virus-based gene therapy researchImmunotherapy and Immune Responses

Cited by 320

An RNA toolbox for cancer immunotherapy

Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 229

Molecular pathways: hypoxia response in immune cells fighting or promoting cancer

Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research

Cancer, Hypoxia, and MetabolismImmune cells in cancer

Cited by 214

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

Paiva, B., Azpilikueta, A., Puig, N., Ocio, E. M., Sharma, R., Oyajobi, B. O., Labiano, S., San-Segundo, L., Rodriguez, A., Aires-Mejia, I., et al. (2015) · Leukemia

Cancer Immunotherapy and BiomarkersMultiple Myeloma Research and Treatments

Cited by 192

T cell migration from inflamed skin to draining lymph nodes requires intralymphatic crawling supported by ICAM-1/LFA-1 interactions

Teijeira, A., Hunter, M. C., Russo, E., Proulx, S. T., Frei, T., Debes, G. F., Coles, M., Melero, I., Detmar, M., Rouzaut, A., et al. (2017) · Cell Reports

Lymphatic System and DiseasesCell Adhesion Molecules Research

Cited by 113

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 101

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Segal, N. H., Melero, I., Moreno, V., Steeghs, N., Marabelle, A., Rohrberg, K., Rodriguez-Ruiz, M. E., Eder, J. P., Eng, C., Manji, G. A., et al. (2024) · Nature Communications

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 80

Transient and Intensive Pharmacological Immunosuppression Fails to Improve AAV-based Liver Gene Transfer in Non-Human Primates

Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine

Virus-based gene therapy researchRNA Interference and Gene Delivery

Cited by 69

Repurposing the yellow fever vaccine for intratumoral immunotherapy

Aznar, M. A., Molina, C., Teijeira, A., Rodriguez, I., Azpilikueta, A., Garasa, S., Sanchez‐Paulete, A. R., Cordeiro, L., Etxeberria, I., Alvarez, M., et al. (2020) · EMBO Molecular Medicine

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 44

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes

Labiano, S., Meléndez-Rodríguez, F., Palazón, A., Teijeira, Á., Garasa, S., Etxeberria, I., Aznar, M. Á., Sánchez-Paulete, A. R., Azpilikueta, A., Bolaños, E., et al. (2017) · OncoImmunology

Cancer, Hypoxia, and MetabolismCancer Immunotherapy and Biomarkers

Cited by 35